Correlation of serum S100B concentration with hospital stay in patients undergoing CABG

Ljuba Krnjak1, Primoz Trunk, Borut Gersak

  • 1Clinical Institute of Clinical Chemistry and Clinical Biochemistry, University Medical Center, Ljubljana, Slovenia. ljuba.krnjak@kclj.si

Acta Clinica Croatica
|April 25, 2009
PubMed

Insights

Serum S100B protein levels on postoperative days 1 and 5 correlate with hospital stay length in coronary artery bypass grafting patients. This suggests S100B may predict outcomes even without evident cerebral injury.

Area of Science:

  • Biochemistry
  • Neurology
  • Cardiovascular Surgery

Background:

  • S100B protein is a potential serum marker for cerebral injury following cardiac surgery.
  • Assessing predictive markers for patient outcomes after coronary artery bypass grafting (CABG) is crucial.

Purpose of the Study:

  • To investigate the correlation between serum S100B protein concentration and hospital stay duration in CABG patients.
  • To determine if elevated S100B levels post-surgery predict longer hospitalizations, even in the absence of clinical neurological deficits.

Main Methods:

  • Serum S100B levels were measured preoperatively, immediately post-operation, and on postoperative days 1 and 5 in 32 CABG patients.
  • Multivariate linear regression analysis was employed to assess correlations, controlling for operation type and patient characteristics.

Main Results:

  • Median hospital stay was 7 days (range: 5-34 days).
  • Serum S100B concentrations were significantly elevated post-operation and on day 1 and day 5 compared to preoperative levels.
  • S100B levels on postoperative day 1 (p=0.0296) and day 5 (p=0.0021) independently correlated with length of hospital stay.

Conclusions:

  • Postoperative serum S100B concentration on days 1 and 5 may serve as a prognostic indicator for hospital stay duration in CABG patients.
  • These findings suggest S100B could predict outcomes even in patients without overt clinical signs of cerebral injury.
  • Further validation in larger patient cohorts is recommended to confirm these preliminary results.

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...